Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer

Free Subscription 02.03.2026 1 Actas Urol Esp (Engl Ed) 1 Adv Sci (Weinh) 1 Antioxidants (Basel) 1 Bioact Mater 1 Biochem Biophys Rep 1 Biosens Bioelectron 2 BJU Int 1 BMC Cancer 1 BMC Med 1 BMC Urol 1 Cancer Discov 3 Cancers (Basel) 1 Cell Death Dis 1 Clin Epigenetics 3 Clin Genitourin Cancer 1 Curr Oncol 1 Diagnostics (Basel) 1 Discov Oncol 2 Diseases 1 Eur J Clin Nutr 1 Eur J Med Res 4 Eur Urol 1 Eur Urol Oncol 1 FEBS Open Bio 1 Front Digit Health 3 Front Immunol 1 Front Oncol 3 Genes (Basel) 1 Gulf J Oncolog 1 Int J Surg 2 Int Urol Nephrol 1 J Biol Chem 1 J Cell Mol Med 1 J Exp Clin Cancer Res 2 J Transl Med 1 JAAPA 1 Magn Reson Med Sci 1 Medicina (Kaunas) 1 Minerva Urol Nephrol 1 Mol Biol Rep 1 Mol Cancer 1 Mol Cancer Res 1 Nano Lett 1 Nanomedicine 1 Nat Commun 1 Nat Med 1 Oncol Ther 1 Rev Prat 1 Sci Data 1 Surg Oncol 2 Urol Oncol 1 World J Surg Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Actas Urol Esp (Engl Ed)

1. GUERRERO-RAMOS F
   BCG and Systemic Immunotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Lights and Shadows.
   Actas Urol Esp (Engl Ed). 2026 Feb 23:501936. doi: 10.1016/j.acuroe.2026.501936.
   PubMed        
   
   

   
   Adv Sci (Weinh)

2. YING X, Huang Y, Huang J, Cai Q, et al
   m(5)C-Modified tRF3b-Cys(GCA)-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4.
   Adv Sci (Weinh). 2026 Feb 27:e22294. doi: 10.1002/advs.202522294.
   PubMed         Abstract available
   
   

   
   Antioxidants (Basel)

3. PARADA D, Onoiu AI, Iftimie S, Camps J, et al
   A Pilot Study Exploring Paraoxonase-1 Tissue Protein Expression and Circulating Levels in Bladder Cancer.
   Antioxidants (Basel). 2026;15:198.
   PubMed         Abstract available
   
   

   
   Bioact Mater

4. SHAN M, Wang X, Wang Z, Xu C, et al
   NIR-II aggregation-induced emission sonosensitizer for pyroptosis induction in bladder cancer.
   Bioact Mater. 2026;61:229-242.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Rep

5. HONG X, Wang G, Hong T, Liu X, et al
   Glycolysis-related genes for bladder cancer: A Mendelian randomization analysis.
   Biochem Biophys Rep. 2026;45:102501.
   PubMed         Abstract available
   
   

   
   Biosens Bioelectron

6. WEI X, Cai L, Li N, Fang Y, et al
   High-throughput screening of bladder cancer exosome biomarkers by barcodes integrated herringbone microfluidics.
   Biosens Bioelectron. 2026;302:118545.
   PubMed         Abstract available
   
   

   
   BJU Int

7. SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
   Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
   BJU Int. 2026 Feb 25. doi: 10.1111/bju.70182.
   PubMed         Abstract available
   
   
8. HUMAYUN-ZAKARIA N, Tura BJ, van Hemelrijck M, Bryan RT, et al
   Aligning bladder cancer research with patient needs: an update on research priorities.
   BJU Int. 2026 Feb 27. doi: 10.1111/bju.70206.
   PubMed        
   
   

   
   BMC Cancer

9. ZHANG L, Cao J, Gao Z, Han C, et al
   Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.
   BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15806.
   PubMed        
   
   

   
   BMC Med

10. BAEK SW, Byun YJ, Piao XM, Seo JW, et al
    Transcriptome-based high-frequency recurrence index predicts frequent recurrence in non-muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy.
    BMC Med. 2026 Feb 27. doi: 10.1186/s12916-026-04745.
    PubMed         Abstract available
    
    

    
    BMC Urol

11. HABICHER M, Swoboda C, Hauptmann A, Koch C, et al
    Enhanced recovery after radical cystectomy for bladder cancer: a prospective observational case -control study.
    BMC Urol. 2026 Feb 25. doi: 10.1186/s12894-026-02093.
    PubMed        
    
    

    
    Cancer Discov

12. TRAN MA, Cho BA, Izadmehr S, Yoo SK, et al
    A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancer.
    Cancer Discov. 2026 Feb 27. doi: 10.1158/2159-8290.CD-25-1774.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

13. BEKESCHUS S, Berner J, Edelmann J, Wolff CM, et al
    Synergistic Toxicity of Cold Gas Plasma and Cisplatin in Bladder Cancer Cells.
    Cancers (Basel). 2026;18:675.
    PubMed         Abstract available
    
    
14. GRIER AL, Zhong JY, Basourakos S, Calaway A, et al
    Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2026;18:623.
    PubMed         Abstract available
    
    
15. RIBEIRO E, Vale N
    Personalized Combination Therapy in Bladder Cancer: cAMP Modulators Synergize with 5-FU and Modulate Redox Programs.
    Cancers (Basel). 2026;18:562.
    PubMed         Abstract available
    
    

    
    Cell Death Dis

16. CUI J, Chen S, Liu X, Jiang X, et al
    PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6.
    Cell Death Dis. 2026 Feb 23. doi: 10.1038/s41419-026-08498.
    PubMed         Abstract available
    
    

    
    Clin Epigenetics

17. LUO C, Kuang X, Dai Y, Cai Z, et al
    DNA methylation-mediated silencing of HNF1B promotes bladder cancer progression.
    Clin Epigenetics. 2026 Feb 21. doi: 10.1186/s13148-026-02079.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

18. SAKTHIVEL DK, Prabhakar P, Iyub MJR, Garje R, et al
    Comparative Analysis of Signet Ring and Non-Signet Ring Urachal Adenocarcinomas: A National Cancer Database Study.
    Clin Genitourin Cancer. 2026;24:102495.
    PubMed         Abstract available
    
    
19. TAWAGI K, Khaki AR, Chablani PV, Hoffman-Censits J, et al
    Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.
    Clin Genitourin Cancer. 2026;24:102487.
    PubMed         Abstract available
    
    
20. SEO J, Park JM, Park DJ, Seo I, et al
    Exploration of the Tumor Transcriptomic and Immune Landscape Following Repeated Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Jan 23:102513. doi: 10.1016/j.clgc.2026.102513.
    PubMed         Abstract available
    
    

    
    Curr Oncol

21. BUONERBA C, Baio R, Crocetto F, Bruzzese D, et al
    BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG.
    Curr Oncol. 2026;33:128.
    PubMed         Abstract available
    
    

    
    Diagnostics (Basel)

22. OZYURT N, Turhan A
    Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.
    Diagnostics (Basel). 2026;16:574.
    PubMed         Abstract available
    
    

    
    Discov Oncol

23. LI Y, Ma Y, Lai J, Wan Q, et al
    Exploring the potential mechanisms of hydroquinone on bladder cancer using network toxicology, Mendelian randomization analysis, molecular docking, and molecular dynamics simulations.
    Discov Oncol. 2026 Feb 27. doi: 10.1007/s12672-025-04114.
    PubMed        
    
    

    
    Diseases

24. PAVALEAN MI, Lambrescu IM, Gaina G, Madan VL, et al
    CD36 rs1761667 Polymorphism and Its Impact on Molecular Signatures in Bladder Cancer.
    Diseases. 2026;14:44.
    PubMed         Abstract available
    
    
25. KATONGTUNG P, Shiangjen K, Cholamjiak W, Naravejsakul K, et al
    MRI-Based Bladder Cancer Staging via YOLOv11 Segmentation and Deep Learning Classification.
    Diseases. 2026;14:45.
    PubMed         Abstract available
    
    

    
    Eur J Clin Nutr

26. HUNDEBOLL JH, Olesen AF, Wessel I, Magkos F, et al
    Not just about weight: Identifying hidden nutritional vulnerability after radical cystectomy.
    Eur J Clin Nutr. 2025 Dec 10. doi: 10.1038/s41430-025-01694.
    PubMed         Abstract available
    
    

    
    Eur J Med Res

27. ZENG S, Xu Z, Xing S, Zhang Y, et al
    Exploratory study of olaparib combined with intravesical perfusion in the treatment of secondary bladder cancer after kidney transplantation: preliminary observations and discussion.
    Eur J Med Res. 2026 Feb 26. doi: 10.1186/s40001-026-04029.
    PubMed         Abstract available
    
    

    
    Eur Urol

28. CLARK PE
    Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
    Eur Urol. 2026 Feb 25:S0302-2838(26)01995-0. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
29. GUPTA S, Li R, Hensley PJ, Daneshmand S, et al
    Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
    Eur Urol. 2026 Feb 21:S0302-2838(26)00059-X. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available
    
    
30. LIU P, Chen J, Zhou J
    Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Feb 24:S0302-2838(26)01997-4. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    
31. NUSBAUM DJ, Li R, Peyton CC, Spiess PE, et al
    Less Is More? How Much Bacillus Calmette-Guerin (BCG) Is Enough for BCG-naive High-risk Non-muscle invasive Bladder Cancer?
    Eur Urol. 2026 Feb 24:S0302-2838(26)02001-4. doi: 10.1016/j.eururo.2026.
    PubMed        
    
    

    
    Eur Urol Oncol

32. SCHMID SC, Jahnen M, Schiller K, Sauter A, et al
    Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).
    Eur Urol Oncol. 2026 Feb 25:S2588-9311(26)00056.
    PubMed         Abstract available
    
    

    
    FEBS Open Bio

33. NIU S, Li L, Jia W, Feng H, et al
    Quantitative proteomic analysis reveals different characteristics of bladder cancer cells after exposure to bisphenol A.
    FEBS Open Bio. 2026 Feb 25. doi: 10.1002/2211-5463.70221.
    PubMed         Abstract available
    
    

    
    Front Digit Health

34. ZHANG L, Zhong Y, Yang G, Huang L, et al
    Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions.
    Front Digit Health. 2026;8:1708289.
    PubMed         Abstract available
    
    

    
    Front Immunol

35. KUCAN BRLIC P, Bellulovich E, Golemac M, Jaksic A, et al
    High PVR protein expression marks clear cell renal cell carcinoma with metastatic spread.
    Front Immunol. 2026;17:1754848.
    PubMed         Abstract available
    
    
36. TRATNJEK L, Janev A, Kuret T, Jerman UD, et al
    The interplay of dietary sugar, chronic inflammation, and bladder cancer: mechanistic insights, evidence, and prevention strategies.
    Front Immunol. 2026;17:1731784.
    PubMed         Abstract available
    
    
37. ZHANG L, Gong Y, Chen J, Li M, et al
    Prognostic significance of calcium signaling-related genes in bladder cancer and the role of ATP2B4 in regulating mitochondrial calcium ion levels via the VDAC1/MCU pathway.
    Front Immunol. 2026;17:1561666.
    PubMed         Abstract available
    
    

    
    Front Oncol

38. ZHANG X, Su S, Liu L, Song F, et al
    Preoperative gamma-glutamyl transferase to lymphocyte ratio predicts recurrence in non-muscle-invasive bladder cancer.
    Front Oncol. 2026;16:1724968.
    PubMed         Abstract available
    
    

    
    Genes (Basel)

39. PEREIRA M, Vale N
    Gene Expression-Guided Drug Repurposing in Oncology: Insights from Antiretroviral Agents in Prostate and Bladder Cancer.
    Genes (Basel). 2026;17:184.
    PubMed         Abstract available
    
    
40. SCHITCU VH, Munteanu VC, Borz MB, Cojocaru I, et al
    Genomic Subtypes and Computational Biomarkers in Non-Muscle-Invasive Bladder Cancer Guiding Optimal Timing of Radical Cystectomy and BCG Response Prediction.
    Genes (Basel). 2026;17:153.
    PubMed         Abstract available
    
    
41. CAN VG
    Molecular Characterization of Muscle-Invasive Bladder Cancer: Key MicroRNAs, Transcription Factors, and Differentially Expressed Genes.
    Genes (Basel). 2026;17:122.
    PubMed         Abstract available
    
    

    
    Gulf J Oncolog

42. GOEL V, Jain A, Basu D, Patnaik N, et al
    Comparative Efficacy and Toxicity of Gemcitabine-Cisplatin vs. Gemcitabine-Carboplatin in Metastatic Carcinoma of the Urinary Bladder: A Retrospective Review.
    Gulf J Oncolog. 2025;1:60-66.
    PubMed         Abstract available
    
    

    
    Int J Surg

43. PAN W, Xing J, Chen X, Xue R, et al
    Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions.
    Int J Surg. 2026;112:4762-4788.
    PubMed         Abstract available
    
    

    
    Int Urol Nephrol

44. PELLEGRINO P, Scherer TP, Wettstein MS, Baumgartner M, et al
    Development of a nomogram for prediction of postoperative bleeding after transurethral resection of bladder tumors.
    Int Urol Nephrol. 2026;58:921-929.
    PubMed         Abstract available
    
    
45. NISHIMURA F, Oniki K, Yamashita A, Honda K, et al
    Prognostic role of intramuscular adipose tissue content in patients with urothelial carcinoma treated with pembrolizumab.
    Int Urol Nephrol. 2026;58:861-871.
    PubMed         Abstract available
    
    

    
    J Biol Chem

46. XU L, Lin Y, Shi G, Zhang L, et al
    Single-Cell Insights into Cisplatin Resistance Mechanisms in Bladder Cancer Tumor Microenvironment.
    J Biol Chem. 2026 Feb 20:111304. doi: 10.1016/j.jbc.2026.111304.
    PubMed         Abstract available
    
    

    
    J Cell Mol Med

47. WALLERSON J, Rostampour S, Teng S, Kidane D, et al
    Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment.
    J Cell Mol Med. 2026;30:e71064.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

48. MUNERA-MARAVILLA E, Perez-Escavy M, Rubio C, Segovia C, et al
    Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models.
    J Exp Clin Cancer Res. 2026 Feb 23. doi: 10.1186/s13046-026-03677.
    PubMed        
    
    

    
    J Transl Med

49. XU DM, Chen J, Lin SB, Xu TY, et al
    ATIC facilitates the malignant progression of bladder cancer by modulating AMPK-mTOR-S6K1 axis under folate reprogramming.
    J Transl Med. 2026 Feb 21. doi: 10.1186/s12967-026-07830.
    PubMed        
    
    
50. HUANG GK, Zhang XX, Huang LY, Un HC, et al
    Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with PD-1 blockade in bladder cancer.
    J Transl Med. 2026 Feb 26. doi: 10.1186/s12967-026-07924.
    PubMed         Abstract available
    
    

    
    JAAPA

51. MISURKA J, Berjaoui MB, Lajkosz K, Cockburn J, et al
    PA- versus urologist-performed flexible cystoscopy: A comparative study.
    JAAPA. 2026;39:34-36.
    PubMed         Abstract available
    
    

    
    Magn Reson Med Sci

52. TAKEUCHI M, Tamada T
    Current Status and Future Perspective for Bladder Cancer MR Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in Japan: Challenges and Solutions.
    Magn Reson Med Sci. 2026 Feb 26. doi: 10.2463/mrms.rev.2025-0213.
    PubMed         Abstract available
    
    

    
    Medicina (Kaunas)

53. MATSUO T, Mori S, Honda H, Kakita S, et al
    Preoperative Gamma-Glutamyltransferase-to-Lymphocyte Ratio as an Independent Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    Medicina (Kaunas). 2026;62:343.
    PubMed         Abstract available
    
    

    
    Minerva Urol Nephrol

54. BENIJTS R, Akand M, Tipirdamaz M, Mennes J, et al
    External validation and comparison of nomograms for prediction of long-term disease recurrence and survival for bladder cancer patients who undergo radical cystectomy.
    Minerva Urol Nephrol. 2026 Feb 27. doi: 10.23736/S2724-6051.25.06600.
    PubMed         Abstract available
    
    

    
    Mol Biol Rep

55. DENG Z, Yan Z, Chen Z
    Post-translational modifications: Principal regulators of bladder cancer.
    Mol Biol Rep. 2026;53:446.
    PubMed        
    
    

    
    Mol Cancer

56. WANG Y, Wu N, Zhang S
    Ferroptosis-autophagy crosstalk in bladder cancer: mechanisms and therapeutic implications.
    Mol Cancer. 2026 Feb 24. doi: 10.1186/s12943-026-02608.
    PubMed        
    
    

    
    Mol Cancer Res

57. ADIB E, Nassar AH, Alaiwi SA, Baca SC, et al
    Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular Subtypes.
    Mol Cancer Res. 2026 Feb 24. doi: 10.1158/1541-7786.MCR-25-1385.
    PubMed         Abstract available
    
    

    
    Nano Lett

58. CHEN C, Yang Y, Niu H, Tang Y, et al
    Interfacial Electric Locking of the Aptamer Conformation for Accurate Liquid Biopsy Detection.
    Nano Lett. 2026;26:2371-2380.
    PubMed         Abstract available
    
    

    
    Nanomedicine

59. REN S, Dai R, Zheng Z, Liu Q, et al
    Corrigendum to "A novel bidirectional perfusion-like administered system for NIR-II fluorescence imaging precision diagnosis of bladder cancer" [Nanomed Nanotechnol Biol Med 49 (April 2023) 102661].
    Nanomedicine. 2026 Feb 25:102916. doi: 10.1016/j.nano.2026.102916.
    PubMed        
    
    

    
    Nat Commun

60. FALQUET M, El Ahanidi H, Gomez-Cadena A, Su Z, et al
    Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.
    Nat Commun. 2026 Feb 21. doi: 10.1038/s41467-026-69841.
    PubMed         Abstract available
    
    

    
    Nat Med

61. MELLEMA JJ, Stockem CF, Herberts C, Cheung SK, et al
    Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
    Nat Med. 2026 Feb 27. doi: 10.1038/s41591-026-04271.
    PubMed         Abstract available
    
    

    
    Oncol Ther

62. DI LORENZO G, Di Maio M, Buonerba C
    Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
    Oncol Ther. 2026 Feb 21. doi: 10.1007/s40487-026-00417.
    PubMed         Abstract available
    
    

    
    Rev Prat

63. PEYROTTES A, Masson-Lecomte A, Aregui A, Meria P, et al
    [Specificities of oncologic surgery in elder patients].
    Rev Prat. 2026;76:60-65.
    PubMed         Abstract available
    
    

    
    Sci Data

64. LEE TJ, Qiu L, Long J, Mach KE, et al
    CystoDS: a multiclass endoscopy image dataset for artificial intelligence-assisted bladder cancer detection.
    Sci Data. 2026 Feb 26. doi: 10.1038/s41597-026-06887.
    PubMed         Abstract available
    
    

    
    Surg Oncol

65. SAHIN KC, Simsekoglu MF, Ozden SB, Ercili B, et al
    Histologic subtypes and divergent differentiations of urothelial carcinoma: Prognostic implications and clinical insights.
    Surg Oncol. 2026;64:102344.
    PubMed         Abstract available
    
    

    
    Urol Oncol

66. STEMPEL MH, Quezada JP, Belz B, Sun F, et al
    Implications of hemoglobin, albumin, lymphocyte, platelet (HALP) score as a predictor of neoadjuvant chemotherapy response in bladder cancer patients.
    Urol Oncol. 2026 Feb 20:111005. doi: 10.1016/j.urolonc.2026.111005.
    PubMed         Abstract available
    
    
67. SHENG Y, Fan L, Zhu S, Wang Y, et al
    Combined and individual effects of neoadjuvant chemotherapy and lymph node dissection on survival in non-muscle-invasive bladder cancer undergoing radical cystectomy.
    Urol Oncol. 2026;44:111039.
    PubMed         Abstract available
    
    

    
    World J Surg Oncol

68. CHEN Q, Wu K, Cai B, Yu X, et al
    LncRNA miR17HG promotes tumor progression through AXIN2 by sponging miR-144-3p in bladder cancer.
    World J Surg Oncol. 2026 Feb 21. doi: 10.1186/s12957-026-04246.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum